Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00134017 · OUTCOME

Relapse

Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer · Source last updated 2018-08-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
2 years

What was measured

Percentage of participants who developed relapse or progressive disease.

Analysis population: The study data was analyzed early after 117 participants had been treated. This was done in order to publish the data and establish a new local standard of care at our institution. Relapse data was not collected on the remaining 25 participants.

Groups in this outcome

Bone Marrow Transplant

Myeloablative bone marrow transplant with a busulfan (Bu), cyclophosphamide (Cy), preparative regimen and post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Bone Marrow Transplant117

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Bone Marrow Transplant44Not reported3453Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        34
        upper Limit
        53
        value
        44
denoms
  1. counts
    1. group Id
      OG000
      value
      117
    units
    Participants
description
Percentage of participants who developed relapse or progressive disease.
dispersion Type
95% Confidence Interval
groups
  1. description
    Myeloablative bone marrow transplant with a busulfan (Bu), cyclophosphamide (Cy), preparative regimen and post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis.
    id
    OG000
    title
    Bone Marrow Transplant
param Type
NUMBER
population Description
The study data was analyzed early after 117 participants had been treated. This was done in order to publish the data and establish a new local standard of care at our institution. Relapse data was not collected on the remaining 25 participants.
reporting Status
POSTED
time Frame
2 years
title
Relapse
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice